Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin H Kolodny

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Journal of Hypertension|February 4, 2010
Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patientsMax J Hilz, Harald Marthol, Stefan Schwab, et al.
Journal of Hypertension|October 6, 2011
Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapyMax J Hilz, Julia Koehn, Edwin H Kolodny, et al.
AJNR. American Journal of Neuroradiology|September 13, 2005
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosisMatilde Inglese, Annette O Nusbaum, Gregory M Pastores, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 17, 2005
Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patientsOrit Neudorfer, Gregory M Pastores, Bai J Zeng, et al.
Molecular Genetics and Metabolism|September 7, 2010
Tay-Sachs disease in Jacob sheepPaola A Torres, Bai Jin Zeng, Brian F Porter, et al.
Plos One|September 10, 2013
Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?Tobias Böttcher, Arndt Rolfs, Christian Tanislav, et al.
Molecular Genetics and Metabolism|October 8, 2010
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Joe T R Clarke, Don J Mahuran, Swati Sathe, et al.
Molecular Genetics and Metabolism|January 2, 2017
Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher RegistryAmal El-Beshlawy, Anna Tylki-Szymanska, Ashok Vellodi, et al.
Journal of Child Neurology|January 20, 2009
Variable expression of a novel PLP1 mutation in members of a family with Pelizaeus-Merzbacher diseaseAviva Fattal-Valevski, Miriam S DiMaio, Fuki M Hisama, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Hypertension|February 4, 2010
Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patientsMax J Hilz, Harald Marthol, Stefan Schwab, et al.
Journal of Hypertension|October 6, 2011
Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapyMax J Hilz, Julia Koehn, Edwin H Kolodny, et al.
AJNR. American Journal of Neuroradiology|September 13, 2005
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosisMatilde Inglese, Annette O Nusbaum, Gregory M Pastores, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 17, 2005
Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patientsOrit Neudorfer, Gregory M Pastores, Bai J Zeng, et al.
Molecular Genetics and Metabolism|September 7, 2010
Tay-Sachs disease in Jacob sheepPaola A Torres, Bai Jin Zeng, Brian F Porter, et al.
Plos One|September 10, 2013
Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?Tobias Böttcher, Arndt Rolfs, Christian Tanislav, et al.
Molecular Genetics and Metabolism|October 8, 2010
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Joe T R Clarke, Don J Mahuran, Swati Sathe, et al.
Molecular Genetics and Metabolism|January 2, 2017
Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher RegistryAmal El-Beshlawy, Anna Tylki-Szymanska, Ashok Vellodi, et al.
Journal of Child Neurology|January 20, 2009
Variable expression of a novel PLP1 mutation in members of a family with Pelizaeus-Merzbacher diseaseAviva Fattal-Valevski, Miriam S DiMaio, Fuki M Hisama, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
Pageof 4